<DOC>
	<DOCNO>NCT00002580</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth breast cancer cell . Hormone therapy use tamoxifen may fight breast cancer block uptake estrogen . Chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy hormone therapy may kill tumor cell . It yet know treatment regimen effective breast cancer . PURPOSE : Randomized phase III trial compare effectiveness tamoxifen ovarian ablation , and/or combination chemotherapy treat premenopausal woman stage I , stage II , stage IIIA breast cancer .</brief_summary>
	<brief_title>Tamoxifen , Ovarian Ablation , and/or Combination Chemotherapy Treating Premenopausal Women With Stage I , Stage II , Stage IIIA Invasive Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare potential benefit adjuvant tamoxifen without ovarian suppression and/or cyclophosphamide , methotrexate , fluorouracil ( CMF ) premenopausal woman stage I-IIIA , unilateral , invasive breast cancer . OUTLINE : This randomize , multicenter study . Patients stratify accord nodal status ( positive v negative unknown ) hospital region . Patients undergo surgical resection without local radiotherapy , appropriate . Radiotherapy begin within 8 week surgery patient randomize arm I III within 4 week completion chemotherapy patient randomize arm II IV . Patients randomize 1 4 treatment arm , preferably within 2 week surgery . Arm I : Beginning within 4 week surgery , patient receive oral tamoxifen daily . Treatment continue 5 year absence disease progression unacceptable toxicity . Arm II : Beginning within 4 week surgery , patient receive tamoxifen arm I cyclophosphamide IV , methotrexate IV , fluorouracil IV ( CMF ) day 1 . Chemotherapy continue every 3 week 6 course . Arm III : Beginning within 4 week surgery , patient receive tamoxifen arm I 1 3 ovarian suppression regimen , preferably regimen A . Regimen B prefer alternative regimen A . Regimen A : Patients undergo oophorectomy . Regimen B : Patients undergo radiation-induced menopause comprise radiotherapy pelvis day 1-4 . Regimen C : Beginning 4 week surgery , patient receive goserelin subcutaneously ( SC ) leuprolide SC intramuscularly day 1 . Treatment continue every 4 week 2 year . Arm IV : Patients receive tamoxifen arm I CMF arm II follow within 4 week ovarian suppression arm III . Patients follow every 6 month 5 year annually thereafter . PROJECTED ACCRUAL : A total 1,000 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven unilateral , invasive breast cancer Stage T03 , N01 , M0 No carcinoma situ alone , include Paget 's disease nipple without underlie invasion No evidence distant disease , include ipsilateral supraclavicular node enlargement unless prove benign No history pure carcinoma situ either breast Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 70 Sex : Female Menopausal status : Premenopausal , define 1 follow criterion : Last menstrual period less 1 year surgery Under age 50 prior hysterectomy ( nonmalignant reason ) without bilateral oophorectomy Under age 50 continuous oral contraception If variance definition , hormonal assay premenopausal range take precedence Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing No serious illness No prior invasive malignancy except adequately treat basal cell squamous cell skin cancer PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>